Stock listing

OTC:BPTH Bio-Path Holdings, Inc. Stock

Follow Bio-Path Holdings, Inc. into a list and get an email when it puts out news.

Bio-Path Holdings, Inc. logo
Ticker
OTC:BPTH
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

Bio-Path Holdings, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
Calls
18 calls with a replay · 18 with a transcript · latest Nov 15, 2024
Decks
11 decks · latest May 2022

Valuation

balance Mar 31, 2026

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
0.50

Forecasts

1 buy · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
2.00 USD · Analysts' mean
EPS, year to Dec 2025
-1.59 · 1 analyst

Team and board

Officers

OfficerRole
Vikram GroverCEO | Board Chairman
Wendy CharlesChief Scientific Officer and Chief Ethics & Compliance Officer

Board

DirectorRole
Wendy CharlesChief Scientific Officer and Chief Ethics & Compliance Officer

Events

Calls

CallWhenStatus
Bio-Path Holdings (OTC:BPTH) Q3 2024 Earnings CallFri, Nov 15, 2024 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q2 2024 Earnings CallThu, Aug 15, 2024 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q1 2024 Earnings CallWed, May 15, 2024 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q4 2023 Earnings CallFri, Mar 08, 2024 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q3 2023 Earnings CallWed, Nov 15, 2023 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q2 2023 Earnings CallTue, Aug 15, 2023 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q1 2023 Earnings CallFri, May 12, 2023 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q4 2022 Earnings CallFri, Mar 31, 2023 · 8:00 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q3 2022 Earnings CallTue, Nov 15, 2022 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q2 2022 Earnings CallTue, Aug 16, 2022 · 8:30 AM ETReplay
All 18 calls
CallWhenStatus
Bio-Path Holdings (OTC:BPTH) Q1 2022 Earnings CallTue, May 17, 2022 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q4 2021 Earnings CallFri, Mar 11, 2022 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q2 2021 Earnings CallFri, Aug 13, 2021 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q1 2021 Earnings CallFri, May 14, 2021 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q4 2020 Earnings CallWed, Mar 10, 2021 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q3 2020 Earnings CallFri, Nov 13, 2020 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q2 2020 Earnings CallFri, Aug 14, 2020 · 8:30 AM ETReplay
Bio-Path Holdings (OTC:BPTH) Q1 2020 Earnings CallFri, May 15, 2020 · 8:30 AM ETReplay

Results days

QuarterResults
Q2 2025Aug 14, 2025 · After close
Q1 2025May 15, 2025 · After close
Q4 2024Mar 6, 2025 · Before open
Q3 2024Nov 14, 2024 · After close
Q2 2024Aug 14, 2024 · After close
Q1 2024May 14, 2024 · After close
Q4 2023Mar 7, 2024 · After close
Q3 2023Nov 14, 2023 · After close
Q2 2023Aug 14, 2023 · After close
Q1 2023May 11, 2023 · After close
All 19 quarters
QuarterResults
Q4 2022Mar 31, 2023 · Before open
Q3 2022Nov 14, 2022 · After close
Q2 2022Aug 15, 2022 · After close
Q1 2022May 16, 2022 · After close
Q4 2021Mar 10, 2022 · After close
Q3 2021Nov 10, 2021 · After close
Q2 2021Aug 12, 2021 · After close
Q1 2021May 13, 2021 · After close
Quarter to Dec 31, 2020Mar 9, 2021 · After close

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (May 2022)Investor deck12 slidesMay 2022
Investor Presentation (January 2022)Investor deck17 slidesJanuary 2022
Investor Presentation (March 2021)Investor deck17 slidesMarch 2021
Shareholder Meeting (December 2020)Shareholder meeting16 slidesDec 21, 2020
Investor Presentation (May 2019)Investor deck23 slidesMay 2019
Investor Presentation (October 2017)Investor deck20 slidesOctober 2017
Investor Presentation (July 2017)Investor deck22 slidesJuly 2017
Investor Presentation (December 2016)Investor deck22 slidesDec 16, 2016
Investor Presentation (January 2016)Investor deck20 slidesJan 13, 2016
Shareholder Meeting (December 2015)Shareholder meeting20 slidesDec 30, 2015
All 11 decks
DeckKindSlidesDate
TIDES 2015Conference19 slidesMay 2015

Open Decks

Financials

Annual, in USD

Income statement

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue000000037.0K13.0K0
Cost of revenue178.0K178.0K161.0K151.0K230.0K426.0K8.59M8.28M201.8K
Gross profit-178.0K-178.0K-161.0K-151.0K-230.0K-426.0K37.0K13.0K-201.8K
Research and development7.29M11.6M9.16M5.91M6.58M4.58M4.60M5.48M5.47M3.02M
Selling, general and administrative4.70M4.11M4.74M4.53M4.33M4.11M3.38M3.52M3.01M2.46M
Operating income-12.0M-15.8M-13.9M-10.4M-10.9M-8.69M-8.59M-8.97M-8.47M-5.48M
Depreciation and amortization159.0K178.0K178.0K161.0K151.0K230.0K426.0K411.0K204.0K201.8K
EBITDA-11.8M-15.7M-13.7M-10.3M-10.8M-8.46M-8.16M-8.55M-8.27M-5.28M
Interest expense33.0K3.00K000000
Income before tax-9.89M-16.1M-13.9M-10.4M-10.9M-8.60M-8.58M-7.02M-6.75M-5.47M
Income tax-33.0K-3.00K-26.0K-94.0K-608.0K-1.94M-1.73M0
Net income-9.89M-16.1M-13.8M-10.4M-10.9M-8.51M-8.58M-7.02M-6.75M-5.47M
Earnings per share, basic-1.72-33.64-38.03-31.04-56.44-64.02-14.38-13.93-14.56-12.18

Balance sheet

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash and equivalents1.17M1.05M10.4M23.8M13.8M20.4M1.00M5.96M9.38M8.85M
Short-term investments000
Receivables0-3.59K-5230775.2K
Inventory6323.59K5231.27K77600559.5K
Current assets3.78M3.04M15.6M26.1M16.0M22.0M1.93M7.43M10.7M9.59M
Property, plant and equipment428.0K231.0K303.0K406.0K654.0K614.0K72.0K
Goodwill000
Total assets3.88M3.22M16.0M26.6M16.5M22.7M2.33M8.86M12.2M10.8M
Accounts payable1.27M457.0K667.0K106.0K100.0K486.0K813.0K52.0K69.0K54.6K
Current liabilities3.29M1.91M1.68M958.0K1.17M1.24M1.12M791.0K1.05M937.4K
Long-term debt000
Total debt113.0K221.0K235.0K330.0K415.0K
Total liabilities3.73M2.78M1.80M1.11M1.41M1.57M1.12M791.0K3.96M937.4K
Shareholders' equity154.0K441.0K14.2M25.5M15.1M21.1M1.22M8.07M8.24M9.82M
Shares outstanding5.77M478.0K363.8K336.3K192.3K132.8K597.0K504.0K463.5K448.8K

Cash flow

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations-10.6M-11.5M-15.1M-9.92M-11.0M-8.36M-6.12M-7.96M-8.15M-5.00M
Capital spending00-21.0K-70.0K-70.0K-70.0K-17.0K-538.0K-338.0K-338.0K
Free cash flow-10.6M-11.5M-15.1M-9.99M-11.0M-8.36M-6.14M-8.49M-8.49M-5.00M
Cash from investing-70.0K-70.0K-70.0K-17.0K-538.0K-338.0K-338.0K
Cash from financing10.7M2.20M1.73M20.0M4.29M27.8M1.18M5.08M9.01M9.01M
Dividends paid000
Share buybacks4.29M27.8M1.18M5.08M9.01M0
Change in cash121.0K-9.33M-13.4M10.0M-6.67M19.4M-4.96M-3.41M521.0K-5.00M

Open Financials

Cap table

Built by 6ix from Bio-Path Holdings, Inc.’s releases · as of May 20, 2026

Common shares
50,297,451
Fully diluted
50,297,451

Fully diluted

LineSharesAs of
Common shares50,297,451May 20, 2026

Share count over time

CountShares
May 20, 202650,297,451

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Mark P Colonnese
Other companies: Vaxart, Inc. (Chief Financial Officer · Nov 2, 2015 – Apr 3, 2017 · Past); Precipio, Inc. (Chief Financial Officer · Sep 12, 2012 – Feb 18, 2014 · Past); Atherogenics Inc (VP Commercial Operations & CFO · Feb 21, 2006 – Dec 31, 2008 · Past)
Director · Jul 13, 2017 – Mar 28, 2019 · Past
Gillian C Ivers-Read
Other companies: Clovis Oncology Inc (See Remarks · Nov 15, 2011 – Nov 1, 2022 · Past); Pharmion Corp (EVP, Development Operations · Dec 31, 2005 – Mar 7, 2008 · Past)
Director · Sep 10, 2008 – Apr 25, 2014 · Past
Aline SherwoodDirector · Mar 31, 2022 – Jul 30, 2024 · Past
Amy SingDirector · Nov 3, 2014 – Mar 23, 2017 · Past
Douglas P MorrisDirector · Sep 10, 2008 – Jul 30, 2024 · Past
Heath CleaverDirector · Feb 11, 2014 – Jul 30, 2024 · Past
Michael J GarrisonDirector · Oct 1, 2012 – Mar 23, 2017 · Past
Paul AubertDirector · Feb 1, 2018 – Jul 30, 2024 · Past
Peter Henry NielsenPresident, CEO & CFO, Director · Mar 28, 2019 – Jul 30, 2024 · Past
Tamaro Martina MolsbergenDirector · Oct 11, 2019 – Mar 31, 2021 · Past
All 14 people
PersonSeat
Thomas E GarrisonDirector · Sep 10, 2008 – Dec 2, 2009 · Past
Ulrich W MuellerCOO & Secretary · Mar 26, 2014 – May 1, 2017 · Past
Vikram GroverCEO | Board Chairman · Since at least Nov 5, 2026
Wendy CharlesChief Scientific Officer and Chief Ethics & Compliance Officer · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Bio-Path Holdings, Inc.